Severe Asthma Therapeutics Products Market Current Trends Analysis 2026 to 2035

Report Id: 3433 Pages: 179 Last Updated: 04 February 2026 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Severe Asthma Therapeutics Products Market Segmentation:

Severe Asthma Therapeutics Products Market by Therapy Class - 

• Biologics
• Small Molecule / Targeted Immunomodulators
• Optimized Inhaled Add-on Therapies
• Systemic Corticosteroids (Maintenance)
• Interventional Therapies 

Severe Asthma Therapeutics Products Market seg

Severe Asthma Therapeutics Products Market by Drug Target / Mechanism -

• Anti-IgE
• Anti-IL-5
• Anti-IL-5 Receptor (IL-5Rα)
• Anti-IL-4 / IL-13 Pathway (IL-4Rα)
• Anti-TSLP
• Anti-IL-33 / ST2 Axis
• Anti-OX40 / OX40L
• Intracellular Signaling Modulators (JAK, STAT, others)

Severe Asthma Therapeutics Products Market by Phenotype / Endotype-

• Severe Eosinophilic Asthma
• Severe Allergic Asthma
• Type-2 High Severe Asthma
• Type-2 Low / Non-Eosinophilic Severe Asthma
• Oral Corticosteroid-Dependent Severe Asthma

Severe Asthma Therapeutics Products Market by Route of Administration -

• Subcutaneous
• Intravenous
• Inhaled
• Oral

Severe Asthma Therapeutics Products Market by Patient Age Group -

• Pediatric (6–11 Years)
• Adolescent (12–17 Years)
• Adult (18–64 Years)
• Geriatric (65+ Years)

Severe Asthma Therapeutics Products Market by End User -

• Hospitals
• Specialty Clinics (Pulmonology / Allergy)
• Ambulatory Care Centers

Severe Asthma Therapeutics Products Market by Region-

North America-

  • The US
  • Canada

Europe-

  • Germany 
  • The UK
  • France
  • Italy 
  • Spain 
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan 
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa 
  • Rest of Middle East and Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Severe Asthma Therapeutics Market Snapshot

Chapter 4. Global Severe Asthma Therapeutics Market Variables, Trends & Scope

4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends 
4.5. Investment and Funding Analysis 
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2035
4.8. Global Severe Asthma Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2026-2035
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2026)
4.10. Use/impact of AI on Severe Asthma Therapeutics Industry Trends 

Chapter 5. Severe Asthma Therapeutics Market Segmentation 1: By Therapy Class, Estimates & Trend Analysis

5.1. Market Share By Therapy Class, 2025 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Therapy Class:

5.2.1. Biologics
5.2.2. Small Molecule / Targeted Immunomodulators
5.2.3. Optimized Inhaled Add-on Therapies
5.2.4. Systemic Corticosteroids (Maintenance)
5.2.5. Interventional Therapies

Chapter 6. Severe Asthma Therapeutics Market Segmentation 2: By Drug Target / Mechanism, Estimates & Trend Analysis

6.1. Market Share By Drug Target / Mechanism, 2025 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Drug Target / Mechanism:

6.2.1. Anti-IgE
6.2.2. Anti-IL-5
6.2.3. Anti-IL-5 Receptor (IL-5Rα)
6.2.4. Anti-IL-4 / IL-13 Pathway (IL-4Rα)
6.2.5. Anti-TSLP
6.2.6. Anti-IL-33 / ST2 Axis
6.2.7. Anti-OX40 / OX40L
6.2.8. Intracellular Signaling Modulators (JAK, STAT, others)

Chapter 7. Severe Asthma Therapeutics Market Segmentation 3: By Phenotype / Endotype, Estimates & Trend Analysis

7.1. Market Share By Phenotype / Endotype, 2025 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Phenotype / Endotype:

7.2.1. Severe Eosinophilic Asthma
7.2.2. Severe Allergic Asthma
7.2.3. Type-2 High Severe Asthma
7.2.4. Type-2 Low / Non-Eosinophilic Severe Asthma
7.2.5. Oral Corticosteroid-Dependent Severe Asthma

Chapter 8. Severe Asthma Therapeutics Market Segmentation 4: By Route of Administration, Estimates & Trend Analysis

8.1. Market Share By Route of Administration, 2025 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Route of Administration:

8.2.1. Subcutaneous
8.2.2. Intravenous
8.2.3. Inhaled
8.2.4. Oral

Chapter 9. Severe Asthma Therapeutics Market Segmentation 5: By Patient Age Group, Estimates & Trend Analysis

9.1. Market Share By Patient Age Group, 2025 & 2035
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Patient Age Group:

9.2.1. Pediatric (6–11 Years)
9.2.2. Adolescent (12–17 Years)
9.2.3. Adult (18–64 Years)
9.2.4. Geriatric (65+ Years)

Chapter 10. Severe Asthma Therapeutics Market Segmentation 7: By End User, Estimates & Trend Analysis

10.1. Market Share By End User, 2025 & 2035

10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following End User:

10.2.1. Hospitals
10.2.2. Specialty Clinics (Pulmonology / Allergy)
10.2.3. Ambulatory Care Centers

Chapter 11. Severe Asthma Therapeutics Market Segmentation 8: Regional Estimates & Trend Analysis

11.1. Global Severe Asthma Therapeutics Market, Regional Snapshot 2025 & 2035

11.2. North America

11.2.1. North America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035

11.2.1.1. US
11.2.1.2. Canada

11.2.2. North America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Therapy Class, 2022-2035
11.2.3. North America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Drug Target / Mechanism, 2022-2035
11.2.4. North America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Phenotype / Endotype, 2022-2035
11.2.5. North America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2022-2035
11.2.6. North America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Patient Age Group, 2022-2035
11.2.7. North America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By End User, 2022-2035

11.3. Europe

11.3.1. Europe Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035

11.3.1.1. Germany
11.3.1.2. U.K.
11.3.1.3. France
11.3.1.4. Italy
11.3.1.5. Spain
11.3.1.6. Rest of Europe

11.3.2. Europe Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Therapy Class, 2022-2035
11.3.3. Europe Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Drug Target / Mechanism, 2022-2035
11.3.4. Europe Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Phenotype / Endotype, 2022-2035
11.3.5. Europe Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2022-2035
11.3.6. Europe Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Patient Age Group, 2022-2035
11.3.7. Europe Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By End User, 2022-2035

11.4. Asia Pacific

11.4.1. Asia Pacific Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035

11.4.1.1. India 
11.4.1.2. China
11.4.1.3. Japan
11.4.1.4. Australia
11.4.1.5. South Korea
11.4.1.6. Hong Kong
11.4.1.7. Southeast Asia
11.4.1.8. Rest of Asia Pacific

11.4.2. Asia Pacific Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Therapy Class, 2022-2035
11.4.3. Asia Pacific Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Drug Target / Mechanism, 2022-2035
11.4.4. Asia Pacific Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Phenotype / Endotype, 2022-2035
11.4.5. Asia Pacific Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2022-2035
11.4.6. Asia Pacific Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Patient Age Group, 2022-2035
11.4.7. Asia Pacific Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By End User, 2022-2035

11.5. Latin America

11.5.1. Latin America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035

11.5.1.1. Brazil
11.5.1.2. Mexico
11.5.1.3. Rest of Latin America

11.5.2. Latin America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Therapy Class, 2022-2035
11.5.3. Latin America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Drug Target / Mechanism, 2022-2035
11.5.4. Latin America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Phenotype / Endotype, 2022-2035
11.5.5. Latin America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2022-2035
11.5.6. Latin America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Patient Age Group, 2022-2035
11.5.7. Latin America Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By End User, 2022-2035

11.6. Middle East & Africa

11.6.1. Middle East & Africa Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2035

11.6.1.1. GCC Countries
11.6.1.2. Israel
11.6.1.3. South Africa
11.6.1.4. Rest of Middle East and Africa

11.6.2. Middle East & Africa Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Therapy Class, 2022-2035
11.6.3. Middle East & Africa Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Drug Target / Mechanism, 2022-2035
11.6.4. Middle East & Africa Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Phenotype / Endotype, 2022-2035
11.6.5. Middle East & Africa Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2022-2035
11.6.6. Middle East & Africa Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Patient Age Group, 2022-2035
11.6.7. Middle East & Africa Severe Asthma Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By End User, 2022-2035

Chapter 12. Competitive Landscape

12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
 
12.2.1. AB Science
12.2.1.1. Business Overview
12.2.1.2. Key Product/Service
12.2.1.3. Financial Performance
12.2.1.4. Geographical Presence
12.2.1.5. Recent Developments with Business Strategy
12.2.2. AER Therapeutics
12.2.3. Amgen
12.2.4. Apogee Therapeutics
12.2.5. Areteia Therapeutics
12.2.6. AstraZeneca
12.2.7. Bio-Thera Solutions
12.2.8. Biosion
12.2.9. CSPC ZhongQi Pharmaceutical Technology
12.2.10. Generate:Biomedicines
12.2.11. GlaxoSmithKline (GSK)
12.2.12. Incyte
12.2.13. Insmed
12.2.14. Kinaset Therapeutics
12.2.15. Kymera Therapeutics
12.2.16. Lanier Biotherapeutics
12.2.17. Novartis
12.2.18. Oneness Biotech
12.2.19. Regeneron Pharmaceuticals
12.2.20. Roche
12.2.21. Sanofi
12.2.22. Suzhou Connect Biopharmaceuticals
12.2.23. Teva Pharmaceutical Industries
12.2.24. Upstream Bio

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
4525
Security Code field cannot be blank!

Frequently Asked Questions

Severe Asthma Therapeutics Products Market Size is predicted to grow at a 6.9% CAGR during the forecast period for 2026 to 2035.

AB Science, AER Therapeutics, Amgen, Apogee Therapeutics, Areteia Therapeutics, AstraZeneca, Bio-Thera Solutions, Biosion, CSPC ZhongQi Pharmaceutical Technology, Generate:Biomedicines, GlaxoSmithKline (GSK), Incyte, Insmed, Kinaset Therapeutics, Kymera Therapeutics, Lanier Biotherapeutics, Novartis, Oneness Biotech, Regeneron Pharmaceuticals, Roche, Sanofi, Suzhou Connect Biopharmaceuticals, Teva Pharmaceutical Industries, Upstream Bio

Severe Asthma Therapeutics Products Market is segmented in By Therapy Class, By Drug Target / Mechanism, Phenotype / Endotype, Route of Administration, Patient Age Group, End User and By Region

North America region is leading the Severe Asthma Therapeutics Products Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying